DRG Market Assessment reports

The breast cancer treatment landscape is rapidly evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) plus endocrine therapy are entrenched first-line…

Clarivate Epidemiology’s coverage of Rett syndrome comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

Clarivate Epidemiology’s coverage of retinitis pigmentosa comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France,…

Glucagon-like peptide-1 (GLP-1) receptor agonists, like SC semaglutide and liraglutide, and the glucose-dependent insulinotropic polypeptide (GIP) / GLP-1 receptor agonist tirzepatide have gained…

Clarivate Epidemiology’s coverage of essential thrombocythemia (ET) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Clarivate Epidemiology’s coverage of atrial fibrillation (AF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AF for each…

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder in which the immune system attacks red blood cells and platelets. PNH is characterized by intravascular hemolysis, venous…

Clarivate Epidemiology’s coverage of atrial fibrillation (AF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AF for each…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key atrial fibrillation patient populations covering 171 countries and…

Clarivate Epidemiology’s coverage of atrial fibrillation (AF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence…

Clarivate Epidemiology’s coverage of Angelman syndrome comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Agents for treating major depressive disorder (MDD) span multiple drug classes; while selective serotonin reuptake inhibitors (SSRIs) and serotonin / norepinephrine reuptake inhibitors (SNRIs) are…